William G. Cance MD is a transformative physician executive and oncology Key Opinion Leader with a proven track record of strategic, operational, and scientific accomplishments. He has held leadership roles across academic health systems, non-profit organizations, and National Cancer Institute-designated comprehensive cancer centers. He collaborates with diverse stakeholders to influence, define, and execute visionary cancer care and research. Dr. Cance maintained an active clinical practice in surgical oncology/endocrine surgery for 25+ years. He is a successful physician-scientist with continuous peer-reviewed funding for 25+ years from the National Institute of Health, conducting pioneering work on cancer diagnosis and treatment. Dr. Cance is a forward-thinking strategic leader with broad interdisciplinary experience who consistently executes through challenging circumstances. The American Cancer Society named him chief medical and scientific officer in 2019. He has guided the society through a restructuring of their research and patient care services. This included enhancing the cancer cohort studies at the ACS through the embrace of genomic technologies and the launch of significant programs in health equity through the support of minority-serving institutions. Before joining the American Cancer Society, Dr. Cance was deputy director and interim director of the University of Arizona Cancer Center. He led the integration of the university’s Tucson- and Phoenix-based research programs. Dr. Cance was also the Finley & Florence Brown Professor of Cancer Research at the University of Arizona and Professor of Interdisciplinary Oncology and Surgery at the University of Arizona College of MedicinePhoenix. He was chair of the Arizona Cancer Coalition for the Arizona Department of Health Services, during which he focused on promoting programs that addressed cancer disparities in underserved populations. As a practicing surgical oncologist and endocrine surgeon, Dr. Cance specializes in thyroid cancer, parathyroid disease, and soft tissue sarcoma. He is a past president of the Society of Surgical Oncology. As the principal investigator for a 25-year National Cancer Institute R01 grant, he conducted pioneering research on focal adhesion kinase (FAK), a protein involved in cancer metastasis. Recently, he identified FAK as a biomarker of increased recurrence risk in early-stage colorectal cancer*. He has received additional grant funding from the NCI and the US Department of Defense. He holds eight patents and continues to be involved in several entrepreneurial projects to bring his research advancements to commercialization. Dr. Cance earned undergraduate and medical degrees from Duke University. He completed a residency in general surgery at Barnes-Jewish Hospital/Washington University School of Medicine and a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center.